EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Chlorpromazine's Potential Role in Palliating Distressing Symptoms Associated With Hyperactive Delirium in Patients at End of Life

Casey M Tiefenthaler, Jeremy M Hirst, Kyle P Edmonds iD, Rabia S Atayee iD

Journal of Palliative Medicine · 2023-06 · 26 (6) · 826-830

DOI: 10.1089/jpm.2022.0308 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Journal of Palliative Medicine, online erschienen am 02.06.2023. Verfasst von Casey M Tiefenthaler und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, University of California Health, La Jolla, California, USA. Hauptthemen laut MEDLINE: Delirium, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The hyperactive subtype of delirium is characterized by agitation, restlessness, delusions, and/or hallucinations, which commonly present near end of life (EoL). Symptom relief often requires the use of medications, such as chlorpromazine (CPZ), to reduce patient distress by inducing proportional sedation.

Objective

The purpose of this study was to evaluate CPZ's potential role in managing the distress of hyperactive delirium in patients receiving EoL care.

Methods

A retrospective observational study among hospitalized patients with advanced cancer at EoL between January 2020 to December 2021.

Results

Sustained improvement in symptoms of delirium was seen in 80% of patients as identified in the palliative psychiatrist's progress notes. Meanwhile, 75% of patient's improvement was reported in nursing-driven Delirium Observation Screening Scale.

Conclusion

This study elucidates that at doses of ∼100 mg/day, CPZ is potentially an effective medication for patients with advanced cancer, experiencing hyperactive delirium in their final week of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DeliriumNeoplasmsHumansChlorpromazinePsychomotor AgitationDeathPalliative Care

Stichwörter der Autor:innen

chlorpromazineend of lifehyperactive deliriumpalliative careproportionate sedation

Substanzen

Chlorpromazine

Autor:innen und Institutionen

  • Department of Pharmacy, University of California Health, La Jolla, California, USA.
  • Division of Geriatrics, Gerontology, and Palliative Care, Department of Medicine, UC San Diego Section of Palliative Care, La Jolla, California, USA.
  • Palliative Care Program, University of California San Diego, San Diego, California, USA.
  • Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.

ORCID-Profile: Kyle P Edmonds, Rabia S Atayee

Zitieren

APA

Tiefenthaler, C. M., Hirst, J. M., Edmonds, K. P., & Atayee, R. S. (2023). Chlorpromazine's Potential Role in Palliating Distressing Symptoms Associated With Hyperactive Delirium in Patients at End of Life. Journal of Palliative Medicine, 26(6), 826-830. https://doi.org/10.1089/jpm.2022.0308

Vancouver

Tiefenthaler CM, Hirst JM, Edmonds KP, Atayee RS. Chlorpromazine's Potential Role in Palliating Distressing Symptoms Associated With Hyperactive Delirium in Patients at End of Life. Journal of Palliative Medicine. 2023;26(6):826-830. doi:10.1089/jpm.2022.0308

BibTeX
@article{Tiefenthaler2023,
  author = {Tiefenthaler, Casey M and Hirst, Jeremy M and Edmonds, Kyle P and Atayee, Rabia S},
  title = {Chlorpromazine's Potential Role in Palliating Distressing Symptoms Associated With Hyperactive Delirium in Patients at End of Life},
  journal = {Journal of Palliative Medicine},
  year = {2023},
  volume = {26},
  number = {6},
  pages = {826--830},
  doi = {10.1089/jpm.2022.0308}
}
Kostenlos starten →